Marek Jankowski
- Expression of transforming growth factor β (TGFβ) receptor, CD105, is declined in Th1 interstitial lung diseases (ILDs)By Andrzej Dyczek, Jerzy Szczeklik, Barbara Balicka-Slusarczyk, Joanna Chorostowska, Adam Szpechcinski, Ewelina Pόlgesek, Marek Jankowski and Piotr KopinskiAndrzej Dyczek1II Dept of Internal Medicine, Centre of Immunological Diseases, Collegium Medicum, Jagiellonian University, Krakow, PolandJerzy Szczeklik1II Dept of Internal Medicine, Centre of Immunological Diseases, Collegium Medicum, Jagiellonian University, Krakow, PolandBarbara Balicka-Slusarczyk2Dept of Toxicology and Environmental Diseases, Collegium Medicum, Jagiellonian University, Krakόw, PolandJoanna Chorostowska3Laboratory of Molecular Diagnostics and Immunology, Institute of Tuberculosis and Lung Diseases, Warszawa, PolandAdam Szpechcinski3Laboratory of Molecular Diagnostics and Immunology, Institute of Tuberculosis and Lung Diseases, Warszawa, PolandEwelina Pόlgesek4Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandMarek Jankowski4Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandPiotr Kopinski4Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Humanized S.typhi flagellin (FliC) transfected non-small cell lung cancer (NSCLC) cells induce local inflammatory and necrotic changes in an experimental modelBy Marek Jankowski, Janusz Kowalewski, Tomasz Wandtke, Robert Lenartowski, Piotr Kopinski, Maciej Dancewicz and Tomasz TyrakowskiMarek Jankowski1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandJanusz Kowalewski2Dept of Thorax and Tumor Surgery, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandTomasz Wandtke1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandRobert Lenartowski3Dept of Clinical Pathobiochemistry, Nicolaus Copernicus University, Bydgoszcz, PolandPiotr Kopinski1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandMaciej Dancewicz2Dept of Thorax and Tumor Surgery, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandTomasz Tyrakowski4Dept of Clinical Pathobiochemistry and Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Intratumoral injection of plasmid-encoded flagellin inhibits growth of NSCLC-cells in murine lung cancer modelBy Marek Jankowski, Tomasz Wandtke, Robert Lenartowski, Olga Haus and Piotr KopinskiMarek Jankowski1Gene Therapy, Nicolaus Copernicus University, Bydgoszcz, PolandTomasz Wandtke1Gene Therapy, Nicolaus Copernicus University, Bydgoszcz, PolandRobert Lenartowski3Genetics, Nicolaus Copernicus University, Torun, PolandOlga Haus2Clinical Genetics, Nicolaus Copernicus University, Bydgoszcz, PolandPiotr Kopinski1Gene Therapy, Nicolaus Copernicus University, Bydgoszcz, Poland
- Interleukin 27 (IL27): A new tool for lung cancer gene immunotherapy?By Tomasz Wandtke, Marek Jankowski, Piotr Kopinski, Mariusz Bella, Janusz Kowalewski, Adam Szpechcinski and Ewelina PólgesekTomasz Wandtke1Dept. of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandMarek Jankowski1Dept. of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandPiotr Kopinski1Dept. of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandMariusz Bella2Dept. of Chest and Tumor Surgery, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandJanusz Kowalewski2Dept. of Chest and Tumor Surgery, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAdam Szpechcinski3Laboratory of Molecular Diagnostics and Immunology, Institute of Tuberculosis and Lung Diseases, Warszawa, PolandEwelina Pólgesek1Dept. of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Interleukin 27 (IL27) as a novel therapeutic tool in lung cancer immune therapyBy Tomasz Wandtke, Marek Jankowski, Ewelina Wedrowska, Karina Szablowska, Joanna Golinska, Joanna Wielikdzien, Janusz Kowalewski and Piotr KopinskiTomasz Wandtke1Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandMarek Jankowski1Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandEwelina Wedrowska1Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandKarina Szablowska1Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandJoanna Golinska1Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandJoanna Wielikdzien1Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandJanusz Kowalewski2Chest and Tumor Surgery, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandPiotr Kopinski1Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
- Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA moleculesBy Maciej Gawronski, Piotr Kopinski, Marek Jankowski, Arkadiusz Goede, Adam Szpechcinski and Joanna ChorostowskaMaciej Gawronski1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandPiotr Kopinski1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandMarek Jankowski2Dept of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandArkadiusz Goede1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAdam Szpechcinski3Dept of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warszawa, PolandJoanna Chorostowska3Dept of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warszawa, Poland
- Studies on hepatocyte growth factor (HGF) in bronchoalveolar lavage (BAL) do not support the concept on its antifibrotic properties in idiopathic pulmonary fibrosis (IPF)By Piotr Kopinski, Joanna Chorostowska, Grzegorz Przybylski, Andrzej Dyczek, Ewelina Wedrowska, Marek Jankowski, Adam Szpechcinski, Agata Gizycka and Joanna GolinskaPiotr Kopinski1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandJoanna Chorostowska2Dept of Molecular Diagnostics and Immunology, Institute of Tuberculosis and Lung Diseases, Warszawa, PolandGrzegorz Przybylski3Dept of Lung Diseases and Tuberculosis, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAndrzej Dyczek4The Cardiology Outpatient Clinic, John Paul II Hospital, Krakow, PolandEwelina Wedrowska1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandMarek Jankowski5Dept of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, PolandAdam Szpechcinski2Dept of Molecular Diagnostics and Immunology, Institute of Tuberculosis and Lung Diseases, Warszawa, PolandAgata Gizycka2Dept of Molecular Diagnostics and Immunology, Institute of Tuberculosis and Lung Diseases, Warszawa, PolandJoanna Golinska1Dept of Gene Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.